ATE347908T1 - Vorbeugung von gewebeadhäsion - Google Patents
Vorbeugung von gewebeadhäsionInfo
- Publication number
- ATE347908T1 ATE347908T1 AT03702560T AT03702560T ATE347908T1 AT E347908 T1 ATE347908 T1 AT E347908T1 AT 03702560 T AT03702560 T AT 03702560T AT 03702560 T AT03702560 T AT 03702560T AT E347908 T1 ATE347908 T1 AT E347908T1
- Authority
- AT
- Austria
- Prior art keywords
- post
- operative
- adhesions
- prevention
- formation
- Prior art date
Links
- 208000031737 Tissue Adhesions Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 3
- 238000005755 formation reaction Methods 0.000 abstract 3
- 206010060932 Postoperative adhesion Diseases 0.000 abstract 2
- 230000002980 postoperative effect Effects 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0201983A GB2384428A (en) | 2002-01-29 | 2002-01-29 | Inhibitors of HIF |
GB0202379A GB2384706A (en) | 2002-02-04 | 2002-02-04 | Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation |
GB0225128A GB0225128D0 (en) | 2002-10-29 | 2002-10-29 | Laparoscopy and adhesion formation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE347908T1 true ATE347908T1 (de) | 2007-01-15 |
Family
ID=27669901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03702560T ATE347908T1 (de) | 2002-01-29 | 2003-01-29 | Vorbeugung von gewebeadhäsion |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050163781A1 (de) |
EP (1) | EP1482975B1 (de) |
AT (1) | ATE347908T1 (de) |
DE (1) | DE60310383T2 (de) |
WO (1) | WO2003063904A2 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US20050049309A1 (en) * | 2003-07-14 | 2005-03-03 | Lynn Kirkpatrick | Regulation of HIF protein levels via deubiquitination pathway |
JP2007515966A (ja) | 2003-12-23 | 2007-06-21 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 疾患の併用療法のための組成物および方法 |
WO2006026485A2 (en) * | 2004-08-25 | 2006-03-09 | Isis Pharmaceuticals, Inc. | Modulation of hif1-beta expression |
MX2007011735A (es) | 2005-03-24 | 2008-03-14 | Thrombogenics Nv | Anticuerpo anti-plgf novedoso. |
US20080241270A1 (en) * | 2007-03-30 | 2008-10-02 | Neal Robert A | Fluid composition for inhibiting surgical adhesion formation and related method of production |
WO2009020119A1 (ja) * | 2007-08-06 | 2009-02-12 | Senju Pharmaceutical Co., Ltd. | HIF-1αおよびHIF-2α発現阻害物質含有医薬 |
EP2785739B1 (de) | 2011-12-01 | 2017-03-15 | ThromboGenics N.V. | Verbesserung eines augendrucksenkungsergebnisses |
ES2851386T3 (es) * | 2013-12-18 | 2021-09-06 | Csl Ltd | Método de tratamiento de las heridas |
EP3426685A1 (de) | 2016-03-10 | 2019-01-16 | Oxurion NV | Hintere okularfibrosehemmung durch antagonisierung des plazentalen wachstumsfaktors |
CA3019841A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0887076A3 (de) * | 1997-05-07 | 1999-03-31 | Saturnus A.G. | Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle |
TW557297B (en) * | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
US7173038B1 (en) * | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
-
2003
- 2003-01-29 AT AT03702560T patent/ATE347908T1/de not_active IP Right Cessation
- 2003-01-29 DE DE60310383T patent/DE60310383T2/de not_active Expired - Fee Related
- 2003-01-29 US US10/502,639 patent/US20050163781A1/en not_active Abandoned
- 2003-01-29 EP EP03702560A patent/EP1482975B1/de not_active Expired - Lifetime
- 2003-01-29 WO PCT/EP2003/000892 patent/WO2003063904A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1482975B1 (de) | 2006-12-13 |
EP1482975A2 (de) | 2004-12-08 |
DE60310383D1 (de) | 2007-01-25 |
WO2003063904A2 (en) | 2003-08-07 |
WO2003063904A3 (en) | 2004-01-15 |
DE60310383T2 (de) | 2007-09-20 |
US20050163781A1 (en) | 2005-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60310383D1 (de) | Vorbeugung von gewebeadhäsion | |
DE60313624D1 (de) | Derivate von heteroarylnitrilverbindungen | |
DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
TNSN05044A1 (en) | Use of ikappab kinase inhibitors for the treatment of pain | |
IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
NO20055305L (no) | Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase | |
TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
DE60223262D1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
ATE464889T1 (de) | Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
BRPI0311323B8 (pt) | composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação | |
IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
DE69839877D1 (de) | Behandlung und vorbeugung von adhesionen | |
CY1110385T1 (el) | Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης | |
NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
ATE384058T1 (de) | Thiazolderivate | |
EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
ATE429916T1 (de) | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme | |
EA200501513A1 (ru) | Замещённые 1, 4 - диазепины и их применения | |
CY1109950T1 (el) | Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν | |
MX2009004049A (es) | Nuevos derivados de fluoreno, composiciones que los contienen y sus usos como inhibidores de la proteina chaperona hsp90. | |
SE0002739D0 (sv) | New use | |
FI963264A0 (fi) | Tromboksaani A2-välitteisten sairauksien ennaltaestoon ja hoitoon tarkoitettu aine | |
CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος | |
PA8605401A1 (es) | Derivados de 2-aminobenzoilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |